1 year ago

Work programme 2017


Medium-term objective

Medium-term objective MAWP initiative Activity description Timeframe Start End frameworks, including through collaboration with international partners Optimise the current regulatory framework by ensuring efficiency of the existing regulatory operations Provide high quality, efficient and consistent support to medicines development Provide scientific leadership to the ADAPT- SMART project 3.2-6 Analyse experience with legislative provisions, identify gaps in regulatory framework and provide technical support to the EC and the Network in relation to optimising existing regulatory framework, including development and/or implementation of new or amended legislation Develop implementation strategy on companion diagnostics legislation and related guidance documents for the industry 1.3-5 Perform an in-depth review of quality data needed to support the development of a biosimilar medicinal product in a targeted way Before 2017 2016 Before 2017 2015 2015 2017 2016 2017 Resources 2017 Financial resources (cost, thousand Euro) 36,091 Human resources (FTEs) 90 1.2. Initial evaluation activities Activity areas Initial evaluation refers to the process of scientific assessment of medicines submitted for centralised marketing authorisation. It also covers the provision of scientific opinions, in cooperation with the World Health Organization (WHO), on medicinal products for human use that are intended exclusively for markets outside of the European Union (so-called Article 58 applications). The Agency coordinates and performs (through its committees) the scientific evaluation of applications for marketing authorisation, including risk-management plans, and issues opinions that form the basis for the European Commission's decision to grant an EU-wide marketing authorisation. The opinions are based on balancing a medicine's desired effects ('benefits') against the undesired effects ('risks'). Weighing the benefits and risks of a medicine is based on evaluation of a large amount of data relating to quality, safety and efficacy of a medicine. Scientific guidelines are developed to guide applicants with regard to the requirements for demonstrating quality, safety and efficacy of a medicine. The scientific review of the committees’ evaluation is documented in an assessment report, which is made publicly available as a European public assessment report (EPAR). Work programme 2017 EMA/583016/2016 Page 48/123

Drivers The complex path to patient's access to medicines, where marketing authorisation is just one of the steps on the medicine's path to patients, requires a coordinated approach towards robust and sound outcomes. The need to consider the involvement and requirements of other stakeholders leads to increased cooperation with them and decision-making bodies, such as health technology assessment bodies (HTAs), in relation to the exchange of information around the time of licensing, and to introducing a more comprehensive approach for the planning of, and data-generation for postauthorisation measures. Increasing stakeholder expectations to have medicines available to treat various conditions, in combination with the continuous need for flexible and fast reaction to new public-health threats, highlight the importance of contributing to faster patient access to medicines on the market, while maintaining the quality of scientific assessments. To improve the use of various mechanisms for bringing medicines to market, the available regulatory tools that allow patient access to medicines for conditions with unmet medical need, including accelerated assessment and conditional marketing authorisation have been reviewed. The Agency is committed to working in collaboration with the European Commission and the STAMP expert group in the development and implementation of tools to improve timely access of medicines for patients. In an effort to better meet patients' needs, the focus remains on incorporating patients' views and values in the assessment of medicines throughout their lifecycle, including exploring possibilities for involving patients in the benefit-risk assessment process. Transparency of the decision-making process throughout the lifecycle of medicines will remain a key driver. The initial evaluation is thus subject to more intense scrutiny by stakeholders and the community as a whole, with impact on public trust in the Agency's work. This transparency driver also extends to outputs related to the authorisation of medicines, with clear and well-reasoned scientificassessment documentation. Product information on the safe and effective use of a medicine is a key source of information for various stakeholders. The quality and consistency of labelling are therefore under increased scrutiny, as it is important to ensure that the product information meets the needs of users. Workload indicators Results Forecasts 2014 2015 2016 2017 Number of MAA pre-submission meetings 57 102 85 50 Initial evaluation applications, of which: 100 111 114 114 New non-orphan medicinal products 38 36 41 50 New orphan medicinal products 21 25 27 25 Similar biological products 3 12 12 13 Generic, hybrid and abridged products 37 37 31 25 Scientific opinions for non-EU markets (Art 58) 1 1 0 0 Paediatric-use marketing authorisations 0 1 1 1 Number of granted requests for accelerated assessment 12 15 Number of consultations of SAGs / Ad-hoc expert groups in 14 7 8 10 the context of MAAs Reviews on the maintenance of the orphan designation 20 25 Work programme 2017 EMA/583016/2016 Page 49/123

2017 Work Programme
Work Programme 2011 - ERA - Europa
VMGN 11 - Veterinary Medicines Directorate - Defra
IFAH-Europe annual report 2006 - Bundesverband für Tiergesundheit
How TOPRA in Spain will work - presentation
final programme - digital edition - seg/esg congress 2013
ANNUAL REPORT - Bundesverband für Tiergesundheit
Dr. Monica Vinhas de Souza - EHC
MHRA powerpoint template - TOPRA
EFAMA Conference Programme
(CPD) Programme for Pharmaceutical Staff
FP7 ICT Work Programme 2013 - RTD